Zealand Pharma has suffered another setback in its bid to bring glucagon receptor agonist dasiglucagon for ultra-rare disease congenital hyperinsulinism (CHI) to the US market. For the second time ...

A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists—widely used in blockbuster ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are a group of drugs used to treat type 2 diabetes and sometimes obesity. GLP-1 RAs are very effective at lowering blood sugar levels.

Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

and this hormone binds to glucagon receptors in the liver. This binding stimulates breakdown of glycogen and the release of glucose into the circulation. Although glucose is the main mediator of ...

Zhejiang Doer Biologics Co., Ltd. (Doer Bio), a clinical stage biopharmaceutical company, announces that DR10624, its first-in-class (FIC), tri-specific agonist targeting Fibroblast growth factor 21 ...

3 GLP-1 Receptor Activation: Stimulates insulin secretion, delays gastric emptying, and enhances satiety, effectively supporting weight loss.4 Glucagon Receptor Activation: Increases energy ...

About UBT251UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide) and glucagon.